Vidhya Thomas

Mrs. Vidhya Thomas


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2017 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MHMohsen Hedaya
Mohsen Hedaya
VTVidhya Thomas
Vidhya Thomas
MAMohamed E. Abdel-Hamid
Mohamed E. Abdel-Hamid
EKElijah O. Kehinde
Elijah O. Kehinde
OPOludotun Adebayo Phillips
Oludotun Adebayo Phillips
This is a comparative pharmacokinetics study of linezolid (Lzd), and two novel oxazolidinone antibacterial agents—PH027 and PH051—in rabbits to determine if the discrepancy between the in vitro and in vivo activities of the novel compounds is due to pharmacokinetic factors. The pharmacokinetics after IV and oral administration, plasma protein binding and tissue distribution for the three compounds were compared. The elimination half-lives were 52.4 ± 6.3, 68.7 ± 12.1 and 175 ± 46.1 min for Lzd, PH027 and PH051, respectively. The oral bioavailability for Lzd, PH027 and PH051 administered as suspension were 38.7%, 22.1% and 4.73%, which increased significantly when administered as microemulsion to 51.7%, 72.9% and 13.9%. The plasma protein binding were 32–34%, 37–38% and 90–91% for Lzd, PH027 and PH051. The tissue distribution for PH027 and PH051 in all investigated tissues were higher than that for Lzd. It can be concluded that the lower bioavailability of PH027 and PH051 compared to Lzd when administered as suspension is the main cause of their lower in vivo activity, despite their comparable in vitro activity. Differences in the other pharmacokinetic characteristics cannot explain the lower in vivo activity. The in vivo activity of the novel compounds should be re-evaluated using formulations with good oral bioavailability.

28 June 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MHMohsen A. Hedaya
Mohsen A. Hedaya
OPOludotun Adebayo Phillips
Oludotun Adebayo Phillips
VTVidhya Thomas
Vidhya Thomas
MQMohammad Qaddoumi
Mohammad Qaddoumi
SKSamuel Binamin Kombian
Samuel Binamin Kombian
NANaser Altannak
Naser Altannak
Background: We recently synthesized a novel series of triazolyl-oxazolidinones (PH066, PH139, PH162, and PH166) that exhibited significant in vivo anticonvulsant activity in rat models of electrically- and chemically-induced seizures. Objectives: The objectives of the current study were to develop and validate analytical UPLC-MS/MS assays for quantitative determination of these novel compounds in plasma and tissue samples obtained from pharmacokinetic studies to support and/or explain the reported in vivo effects in rats, as well as to study the stability of these compounds in the solid state. Methods: Sensitive, selective, precise, and accurate UPLC-MS/MS methods were developed using a UPLC BEH C18 column for analyte separation. The mobile phase consisted of water with 0.1% formic acid and acetonitrile with 0.1% formic acid in different ratios depending on the analyte of interest. Quantitative determination was performed using the multiple-reaction monitoring scanning mode. The methods were utilized to determine the concentration of the four compounds in plasma and tissue samples obtained at different time points after intraperitoneal (IP) injection of 100 mg/kg of each compound to rats. The stability of the compounds was investigated under forced degradation conditions. Results: The developed methods were specific for each of the analytes and were found to be linear in the concentration range of 5–30 μg/mL in plasma and 0.5–25 μg/g in tissue samples. The intra-day and inter-day precision and accuracies were within the acceptable range for the four compounds. The methods were applied to quantify these compounds in the plasma and various tissue samples obtained from rats after IP administration of 100 mg/kg of each compound. The maximum plasma concentrations were 14.6, 9.20, 14.5, and 18.1 μg/mL, and those of brain were 2.6, 0.22, 1.9, and 2.8 μg/g for PH066, PH139, PH162, and PH166, respectively. The compounds degraded under forced degradation conditions to various degradation products. Conclusions: The developed methods were selective, linear, accurate, and precise and are suitable for quantitation of the four compounds in plasma and tissue samples obtained during pharmacokinetic investigations, as well as for detecting and quantifying their degradation products.

22 September 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MHMohsen A. Hedaya
Mohsen A. Hedaya
MQMohammad Qaddoumi
Mohammad Qaddoumi
VTVidhya Thomas
Vidhya Thomas
NANaser Altannak
Naser Altannak
SKSamuel Binamin Kombian
Samuel Binamin Kombian
OPOludotun Adebayo Phillips
Oludotun Adebayo Phillips
Background/Objectives: Five triazolyl-oxazolidinone derivatives were reported to suppress seizures in rats with different efficacies and durations of action, which may be due to different pharmacokinetic behaviors. This study sought to investigate the pharmacokinetic characteristics of the five selected triazolyl-oxazolidinone derivatives and to correlate these with their anti-seizure activity in rats. A secondary objective was to identify lead compound(s) in this small series for further modification and subsequent development into drug candidates. Methods: Following intraperitoneal injection, the concentrations of the five selected compounds PH066, PH139, PH162, PH166, and PH192, in plasma and brain tissues were measured using LC/MS/MS methods. The brain tissue concentrations for each derivative were subsequently correlated with its observed anti-seizure activity in male Sprague Dawley rats against electrically induced (6 Hz and MES) and chemically-induced (pentylenetetrazole) seizure models. The area under the concentration–time curves in plasma and brain tissues was determined to estimate the average brain distribution of each compound. Anti-seizure activity was quantified using a standardized behavioral scoring system based on the rat’s response to seizure-inducing stimuli, with scores assigned by two independent observers. Results: Plasma and brain tissue concentrations were determined over the duration of each experiment. The mean maximum plasma concentrations were 14.6, 9.20, 14.8, 18.2, and 9.00 μg/mL, while the mean maximum brain tissue concentrations were 2.68, 0.14, 1.94, 2.80, and 0.86 μg/g for PH066, PH139, PH162, PH166, and PH192, respectively. The brain to plasma distribution ratios were in the range of 0.15–0.20 for PH066, PH162, and PH166, but were much lower for PH139 and PH192. The brain tissue concentration for each compound was correlated with its anti-seizure activity. The decreasing order of anti-seizure efficacy against the 6 Hz model was PH162 > PH166 > PH066 > PH139 > PH192, which correlated well with their plasma and brain concentrations. The decreasing order of protection against the MES model was PH139 > PH192 > PH162 > PH066 > PH166, while the decreasing order of protection against the pentylenetetrazole model was PH162 ≈ PH066 > PH166 ≈ PH192 > PH139. Conclusions: Compounds PH066, PH162 and PH166 achieved relatively high plasma and brain tissue concentrations with good plasma to brain distribution ratios. Therefore, they have favorable pharmacokinetic characteristics when compared with compounds PH139 and PH192. Of all the compounds evaluated, PH162 had the best pharmacokinetic characteristics, with consistent moderate to high protection against all the tested seizure models and with sustained anti-seizure activity. Thus, from these studies the order of anti-seizure efficacy and duration of action is PH162 > PH139 > PH166 ≈ PH066 > PH192. Thus, PH162 emerged as the potential lead compound when both pharmacokinetic and pharmacodynamic characteristics are considered.